Thereafter, cell immunostaining for NLRP3 and IL-1β (Figure 7I andFigure S7B-C), an ROS assay (Figure 7J) and ELISA to detect IL-1β (Figure 7H) were performed, which indicated that antagonization of the NF-κB signalling pathway markedly inhibited activation of the NLRP3 inflammasome in CST deficiency. The gene discussed is NLRP3; the disease is hyperinsulinemic hypoglycemia, familial, 4.